The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Oligonucleotide Aptamers: New Tools for Targeted Cancer Therapy
Open accessAbstract
Aptamers are a class of small nucleic acid ligands that are composed of RNA or single-stranded DNA oligonucleotides and have high specificity and affinity for their targets. Similar to antibodies, aptamers interact with their targets by recognizing a specific three-dimensional structure and are thus termed "chemical antibodies." In contrast to protein antibodies, aptamers offer unique chemical and biological characteristics based on their oligonucleotide properties. Hence, they are more suitable for the development of novel clinical applications. Aptamer technology has been widely investigated in various biomedical fields for biomarker discovery, in vitro diagnosis, in vivo imaging, and targeted therapy. This review will discuss the potential applications of aptamer technology as a new tool for targeted cancer therapy with emphasis on the development of aptamers that are able to specifically target cell surface biomarkers. Additionally, we will describe several approaches for the use of aptamers in targeted therapeutics, including aptamer-drug conjugation, aptamer-nanoparticle conjugation, aptamer-mediated targeted gene therapy, aptamer-mediated immunotherapy, and aptamer-mediated biotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Aptamer-Based Multiplexed Proteomic Technology for Biomarker Discovery
Gold, L., Ayers, D., Bertino, J., Bock, C., Bock, A., Brody, E. N., Carter, J., Dalby, A. B., Eaton, B. E., Fitzwater, T., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0015004 · Cited by 1,754
Aptamer to ErbB-2/HER2 enhances degradation of the target and inhibits tumorigenic growth
Mahlknecht, G., Maron, R., Mancini, M., Schechter, B., Sela, M., & Yarden, Y. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1302594110 · Cited by 169
Cited by
DNA Functional Materials Assembled from Branched DNA: Design, Synthesis, and Applications
Dong, Y., Yao, C., Zhu, Y., Yang, L., Luo, D., & Yang, D. (2020) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00294 · Cited by 533
The Medicinal Chemistry of Therapeutic Oligonucleotides
Wan, W. B., & Seth, P. P. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00551 · Cited by 429
New Modalities for Challenging Targets in Drug Discovery
Valeur, E., Guéret, S. M., Adihou, H., Gopalakrishnan, R., Lemurell, M., Waldmann, H., Grossmann, T. N., & Plowright, A. T. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201611914 · Cited by 382
Inorganic nanoparticles: A potential cancer therapy for human welfare
Pugazhendhi, A., Edison, T. N. J. I., Karuppusamy, I., & Kathirvel, B. (2018) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2018.01.034 · Cited by 325
Targeted Nanotheranostics for Future Personalized Medicine: Recent Progress in Cancer Therapy
Jo, S. D., Ku, S. H., Won, Y.-Y., Kim, S. H., & Kwon, I. C. (2016) · Theranostics · doi:10.7150/thno.15335 · Cited by 218
Metadata
- Authors
- Sun, H., Zhu, X., Lu, P. Y., Rosato, R. R., Tan, W., & Zu, Y.
- Venue
- Molecular Therapy - Nucleic Acids
- Publisher
- Elsevier BV
- Published
- 2014-01
- Volume
- 3
- Pages
- e182
- ISSN
- 2162-2531 (ISSN-L)
- OpenAlex
- W2002089022
- Cited by
- 541
- References
- 2
- FWCI
- 20.08
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Oligonucleotide Aptamers: New Tools for Targeted Cancer Therapy. https://app.cochat.ai/papers/10.1038/mtna.2014.32
- The paper
- Sun, H., Zhu, X., Lu, P. Y., Rosato, R. R., Tan, W., & Zu, Y. (2014). Oligonucleotide Aptamers: New Tools for Targeted Cancer Therapy. Molecular Therapy - Nucleic Acids. https://doi.org/10.1038/mtna.2014.32
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
